The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
NeOnc Technologies Holdings (NASDAQ: NTHI) announced promising Phase 2a clinical results for its lead drug NEO100, an intranasally delivered formulation targeting recurrent IDH1-mutant high-grade glioma. Beyond the drug’s efficacy, the company’s extensive patent portfolio on its nose-to-brain delivery platform underpins potential applications in mu…